Triple reuptake inhibitors: a patent review (2006 – 2012)

Bibliography

• Elias LJ, Saucier DM. Neuropsychology: clinical and experimental foundations. Pearson; Boston: 2005
   Google Scholar
• Schultz W. Multiple dopamine functions at different time course. Annu Rev Neurosci 2007;30:259-88
   PubMed Web of Science ®Google Scholar
• Iversen L. Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry 2000;5:357-62
   PubMedGoogle Scholar
• Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003;4:13-25
   PubMed Web of Science ®Google Scholar
• Barlow DH, Durand VM. Abnormal psychology: an integrative approach. 5th edition. Wadsworth Cengage Learning; Belmont, CA: 2009
   Google Scholar
• Preskorn SH, Ross R, Stanga CY. Antidepressants: past, present and future. Springer; Berlin: 2004
   Google Scholar
• Wong DT, Horng JS, Bymaster FP, et al. A selective inhibitor of serotonin uptake: lilly 110140, 3-(p-Trifluoromethylphenoxy)-n-methyl- 3-phenylpropylamine. Life Sci 1974;15:471-9
   PubMed Web of Science ®Google Scholar
• Redrobe JP, Bourin M, Colombel MC, et al. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl) 1998;138:1-8
   PubMed Web of Science ®Google Scholar
• Paul IA. Pharmaceutical news. 2001;8:33
   Google Scholar
• Castrén E. Is mood chemistry? Nat Rev Neurosci 2005;6:241-6
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tomarken AJ. Can recovery from depression be achieved? Psychiatr Serv 2001;52:1469-78
   PubMedGoogle Scholar
• McCabe C, Mishor Z, Cowen PJ, et al. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Bio Psych 2010;67:439-45
   Google Scholar
• El Mansari M, Guiard BP, Chernoloz O, et al. Relevance of norepinephrine- dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 2010;16:e1-17
   Web of Science ®Google Scholar
• Miller HL, Delgado PL, Salomon RM, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Genet Psychiatry 1996;53:117-28
   PubMed Web of Science ®Google Scholar
• Tremblay P, Blier P. Catecholaminergic strategies for the treatment of major depression. Curr Drug Targets 2006;7:149-58
   PubMedGoogle Scholar
• Skolnick P, Popik P, Janowsky A, et al. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol 2003;461:99-104
   PubMed Web of Science ®Google Scholar
• Beer B, Stark J, Krieter P, et al. DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol 2004;44:1360
   PubMed Web of Science ®Google Scholar
• Skolnick P, Popik P, Janowsky A, et al. "Broad spectrum" antidepressants: (-)-1-(3,4-dichlorophenyl)-3-azabicyclo [3,1,0]hexane? Life Sci 2003;73:3175-9
   PubMed Web of Science ®Google Scholar
• Skolnick P, Basile AS. Triple reuptake inhibitors ("broad spectrum" antidepressants). CNS Neurol Disord Curr Drug Targets 2007;6:141-9
   PubMedGoogle Scholar
• Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009;6:53-77
   PubMed Web of Science ®Google Scholar
• Perovic B, Jovanovic M, Miljkovic B, et al. Getting the balance right: established and emerging therapies for major depressive disorders. Neuropsychiatr Dis Treat 2010;6:343-64
   PubMed Web of Science ®Google Scholar
• Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010;167:281-8
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Tran P, Skolnick P, Czobor P, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2012;46:64-71
   PubMed Web of Science ®Google Scholar
• Nowak G, Arnt J, Hyttel J, et al. Down-regulation of dopamine D-2, 5-HT2 receptors and beta-adrenoceptors in rat brain after prolonged treatment with a new potential antidepressant, Lu 19-005. J Neural Transm 1985;64:227-38
   PubMedGoogle Scholar
• Arnt J, Christensen AV, Hyttel J. Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain. Naunyn Schmiedebergs Arch Pharmacol 1985;329:101-7
   PubMedGoogle Scholar
• Res triangle inst. Cocaine receptor binding ligands. WO9309814; 1993
   Google Scholar
• Neurosearch A/S. Process for the preparation of 2-(ethoxymethyl)-tropane derivatives. WO9730997; 1997
   Google Scholar
• Glaxo Group Ltd. Hydrochloride salt and azabicyclo[3,2,1]octane derivative. WO10458; 2008
   Google Scholar
• Boehringer ingelheim international GmbH. Solid pharmaceutical preparation form. WO049024; 2005
   Google Scholar
• Neurosearch A/S. Monoamine neurotransmitter re-uptake inhibitor for neuroprotection. WO028769; 2007
   Google Scholar
• Neurosearch A/S. Monoamine neurotransmitter re-uptake inhibitors for neuroprotection in patients suffering from an advanced stage of a mental disease. WO028770; 2007
   Google Scholar
• Boehringer ingelheim international GmbH. Pharmaceutical composition for the treatment of disorders of sexual desire. WO006738; 2007
   Google Scholar
• Neurosearch A/S. A method for treating-eating disorders. WO065845; 2009
   Google Scholar
• Neurosearch A/S. A method for treating addiction. WO065846; 2009
   Google Scholar
• Neurosearch AS. 8-Azabicyclo[3,2,1]oct-2-ene derivatives, their preparation and use. WO9713770; 1997
   Google Scholar
• Neurosearch A/S. Novel enatiomers and their use as monoamine neurotransmitter re-uptake inhibitors. WO108789; 2006
   Google Scholar
• Neurosearch A/S. Novel azabicyclo[3,2,1]oct-2-ene derivatives and their use as monoamine neurotransmitter-uptake inhibitors. WO025978; 2007
   Google Scholar
• Neurosearch A/S. 8-azabicyclo[3,2,1]oct-2-ene derivatives and their use as mono-amine neurotransmitter re-uptake inhibitors. WO057848; 2010
   Google Scholar
• Boehringer ingelheim international GmbH. Method for producing (1R, 5S) anhydroecgonine ester salts. WO043793; 2009
   Google Scholar
• Neurosearch A/S. (+)- and (-)-8-alkyl-3- (trifluoralkylsulfonyloxy)-8-azabicycl(3,2,1)oct-2-ene. WO108790; 2006
   Google Scholar
• Neurosearch A/S. 3-aryloxy -8-aza-bicyclo[3,2,1]oct-6-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO131525; 2006
   Google Scholar
• Neurosearch A/S. 8-aza-bicyclo[3,2,1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO054531; 2007
   Google Scholar
• Neurosearch A/S. Novel phenylethynyl derivatives of 8-aza-bicyclo[3,2,1]octane and their use as monoamine neurotransmitter re-uptake inhibitors. WO098208; 2009
   Google Scholar
• Neurosearch A/S. Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO093604; 2007
   Google Scholar
• Neurosearch A/S. Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO074797; 2008
   Google Scholar
• Neurosearch A/S. Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO074798; 2008
   Google Scholar
• Neurosearch A/S. Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO130620;2010
   Google Scholar
• Neurosearch A/S. Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO092061; 2011
   Google Scholar
• Neurosearch A/S. Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO117289; 2011
   Google Scholar
• Glaxo Group Ltd. Azabicyclo[3,2,1]octane derivatives. WO056520; 2009
   Google Scholar
• Neurosearch A/S. Novel substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO106090; 2006
   Google Scholar
• Neurosearch A/S. 3, 9-diazabicyclo[3,3,1]nonane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. WO090886; 2007
   Google Scholar
• Neurosearch A/S. Novel 3, 8-diaza-bicyclo[3,2,1]octane- and 3,9-diaza-bicyclo[3,3,1] –noname-3-carboxylic acid ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO109517; 2009
   Google Scholar
• Neurosearch A/S. 1-aza-bicyclo[3,3,1]noname or -3-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO026208; 2010
   Google Scholar
• N.V. Organon. 9-Azabicyclo[3,3,1]nonane derivatives as monoamine reuptake inhibitors. WO039563; 2007
   Google Scholar
• Neuroscienze Pharmaness S.C.AR.L. Diazabicyclic compounds and microemulsions thereof. EP2149370; 2010
   Google Scholar
• Shao L, Hewitt MC, Wang F, et al. Discovery of N-methyl-1-(1-phenylcyclohexyl) methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor. Bioorg Med Chem Lett 2011;21:123-34
   Google Scholar
• Sepracor, Inc. Cycloalkylamines as monoamine reuptake inhibitors. WO081857; 2007
   Google Scholar
• Sepracor, Inc. Triple reuptake inhibitors and methods of their use. WO075064; EP2370405,2010.US20110313013; 2011
   Google Scholar
• Basile AS, Janowsky A, Golembiowska K, et al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther 2007;321:1208-25
   PubMed Web of Science ®Google Scholar
• Skolnick P, Popik P, Janowsky A, et al. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol 2003;461:99-104
   PubMed Web of Science ®Google Scholar
• Skolnick P, Skolnick P, Popik P, et al. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci 2003;73:3175-9
   PubMed Web of Science ®Google Scholar
• Skolnick P, Krieter P, Tizzano J, et al. Antidepressant-like actions of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev 2006;123-34
   PubMedGoogle Scholar
• Dov Pharmaceutical, Inc. (-)-1-(3,4-dichlorophenyl)-3-azabicyclo [3,1,0]hexane, compositions thereof, and uses for treating alcohol-related disorders. WO047837; 2007
   Google Scholar
• Dov Pharmaceutical, Inc. Novel polymorphs of azabicyclohexane. WO023659; 2006
   Google Scholar
• DOV Pharmaceutical, Inc. Methods and compositions for controlling body weight and appetite. WO/063673; 2008
   Google Scholar
• DOV Pharmaceutical, Inc. Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)- 3-azabicyclo[3,1,0]hexane. WO127396; 2007
   Google Scholar
• DOV Pharmaceutical, Inc. Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3,1,0]hexanes. WO013856; 2008
   Google Scholar
• McKinney AA. Preparation and use of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo [3, 1, 0] hexane in the treatment of conditions affected by monoamine neurotransmitters. US0258994; 2012
   Google Scholar
• DOV Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3,1,0]hexanes: preparation and use to treat neuropsychiatric disorders. WO016155; 2007
   Google Scholar
• DOV Pharmaceutical, Inc. Novel 1-heteroaryl-3-azabicyclo [3,1,0]hexanes, methods for their preparation and their use as medicaments. WO153937; 2008
   Google Scholar
• GLAXO Group Ltd. Azabicyclic compounds as serotonine, dopamine and norepinephrine reuptake inhibitors. WO074716; 2008
   Google Scholar
• GLAXO Group Ltd. Compounds. WO027293; 2009
   Google Scholar
• GLAXO Group Ltd. 1,6-disubstituted 3-azabicyclo[3,1,0] hexane derivatives for use as triple reuptake inhibitors. WO141412; 2009
   Google Scholar
• GLAXO Group Ltd. Chemical compounds. WO031771; 2008
   Google Scholar
• Glaxosmithkline. Chemical compounds. US20080114049; 2008
   Google Scholar
• GLAXO Group Ltd. Substituted azabicyclo[4,1,0]heptanes compounds for use as monoamine reuptake inhibitors. WO027294; 2009
   Google Scholar
• GLAXO Group Ltd. 3-azabicyclo[4,1,0] heptanes derivatives useful as norepinephrine, serotonin or dopamine reuptake inhibitors. WO027295; 2009
   Google Scholar
• GLAXO Group Ltd. Novel compounds. WO109608; 2009
   Google Scholar
• GLAXO Group Ltd. Azabicyclo [4,1,0] heptane derivatives and their use as monoamine reuptake inhibitors. WO130672; 2010
   Google Scholar
• GLAXO Group Ltd. Azabicyclo [4,1,0] heptane derivatives and their use as monoamine reuptake inhibitors. WO125033; 2010
   Google Scholar
• GLAXO Group Ltd. Azabicyclo[4,10]heptane derivatives. WO133569; 2010
   Google Scholar
• GLAXO Group Ltd. Tricyclic azabicyclo[4,1,0] heptane derivatives as inhibitors of serotonin, dopamine and norepinepherine re-uptake. WO46025; 2010
   Google Scholar
• Ramot At Tel Aviv University Ltd. Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity. US20100260750; 2010
   Google Scholar
• Kranzler. Prevention and treatment of functional somatic disorders, including stress-related disorders. US20090105222; 2009
   Google Scholar
• SK Holding Co. Ltd. 3-substituted propanamine compounds. WO148290; 2009
   Google Scholar
• SK Holding Co. Ltd. 3- or 4-substituted piperidine compounds. WO148291; 2009
   Google Scholar
• Mayo foundation for medical education and research. Inhibiting neurotransmitter reuptake. WO089479; 2009
   Google Scholar
• Mayo foundation for medical education and research. Inhibiting neurotransmitter reuptake. WO056773; 2011
   Google Scholar
• Pfizer Products, Inc. Diphenyl ether monoamine reuptake inhibitor. WO036881; 2007
   Google Scholar
• Sepracor, Inc. Pyrrolidine triple reuptake inhibitors. WO091268; 2010
   Google Scholar
• Sunovion Pharmacueticals, Inc. Formulations, salts and polymorphs of transnorsertraline and uses thereof. WO069032; 2011
   Google Scholar
• NIFE Therapeutics, S.L. Compounds and methods for selective diversity of olignucleotide molecules to specific neuron types. WO131693; 2011
   Google Scholar
• Sepracor, Inc. Tetralone-based monoamine reuptake inhibitors. WO081542; 2007
   Google Scholar
• F. Hoffmann-La Roche AG. Tetrahydroquinoline indole derivatives as monoamine reuptake inhibitors. WO067273; 2011
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrrolidinyl derivatives and uses thereof. WO115427; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. Aryl ketone as MRI. WO153178; 2009
   Google Scholar
• Otsuka Pharmaceutical Co. Ltd. N, N-substituted 3-aminopyrolidine compounds useful as monoamines reuptake inhibitors. WO121218; 2006
   Google Scholar
• Otsuka Pharmaceutical Co. Ltd. Medicinal material. JP2008137997; 2008
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Pyrrolidine compound. WO123006; 2010
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Heterocyclic compound. WO119528; 2009
   Google Scholar
• Neurosearch A/S. Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO113297; 2004
   Google Scholar
• Neurosearch A/S. Novel piperidine derivatives and their uses as monoamine neurotransmitter re-uptake inhibitors. WO025777; 2008
   Google Scholar
• Neurosearch A/S. Novel N-phenyl- piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO131524; 2006
   Google Scholar
• Neurosearch A/S. 1-phenethylpiperidine derivatives and their use as opioid receptor ligands. WO093603; 2007
   Google Scholar
• Neurosearch A/S. N-aryl-N-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands. WO077574; 2009
   Google Scholar
• Neurosearch A/S. N-aryl-N-piperidin -4-yl-propionamide derivatives and their use as opioid receptor ligands. WO077584; 2009
   Google Scholar
• Neurosearch A/S. N-aryl-N-piperiidin-4-yl-propionamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO077585; 2009
   Google Scholar
• Neurosearch A/S. Novel piperidine-4-carboxylic acid phenyl-alkyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO09173; 2009
   Google Scholar
• Neurosearch A/S. Novel piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO023197; 2010
   Google Scholar
• Neurosearch A/S. Novel piperidine-butyramide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO060852; 2010
   Google Scholar
• Neurosearch A/S. Novel 4-benzhydriyl-tetrahydro-pyridine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO109518; 2009
   Google Scholar
• Neurosearch A/S. Novel 4-benzhydryloxy-tetraalkyl- piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO109519; 2009
   Google Scholar
• Neurosearch A/S. Novel 3,9-diaza-spiro[5,5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO000463; 2007
   Google Scholar
• Neurosearch A/S. Novel 3-aza-spiro[5,5]undec-8-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO000464; 2007
   Google Scholar
• Neurosearch A/S. Novel 3-aza-spiro[5,5]-undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO000465; 2007
   Google Scholar
• Feighner JP. Trazodone, a triazolopyridine derivative, in primary depressive disorder. J Clin Psychiatry 1980.41: 250-5
   Google Scholar
• Auspex Pharmaceuticals, Inc. Substituted triazolopyridines. US0209550; 2009
   Google Scholar
• Neurosearch A/S. 4-Phenyl-piperazin-1-yl- alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO092720; 2009
   Google Scholar
• Neurosearch A/S. Piperazinyl-alkyl- benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. WO032903; 2011
   Google Scholar
• CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. Benzothiophene alkanol piperazine derivatives and their use as antidepressant. WO000198; 2010
   Google Scholar
• CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. The 1-butyl-2-hydroxyyaralkyl piperazine derivatives and their uses as anti-depression medicine therefore. WO040315; 2010
   Google Scholar
• CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. Optical isomers of aralkyl piperazine derivative, preparation methods and uses thereof. WO054185; 2011
   Google Scholar
• CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. Preparation method of optical isomers of 1-butyl-2-hydroxy-aralkyl alcohol piperazine derivative. WO054183; 2011
   Google Scholar
• Brogden RN, Heel RC, Speight TM, Avery GS. Nomifensine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 1979;18:1-24
   PubMedGoogle Scholar
• AMR Technology, Inc & Bristol-Myers Squibb Co. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use therefore to block reuptake of norepinephrine, dopamine and serotonin. WO020049; 2006
   Google Scholar
• Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof. US0292242; 2010
   Google Scholar
• Albany Molecular Research, Inc. 7-([1,2,4] triazolo[1,5-a]pyridine-6-yl)-4-(3, 4-dichlorophenyl)- 1,2,3,4- tetrahydroisoquinoline and use thereof. WO132442; 2010
   Google Scholar
• Bristol-Myers Squib Co. The crystalline forms of (S)-7-([1,2,4]triazolo[1,5a]pyridine-6-yl)-4-(3,4-dichlorophenyl) -1,2,3,4- tetrahydro isoquinoline and use thereof. WO132487; 2010
   Google Scholar
• Panacea Biotec Ltd. Novel monoamine re-uptake inhibitor. WO118765;2009
   Google Scholar
• AMR Technology, Inc & Bristol-Myers Squibb Co. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use therefore to block reuptake of norepinephrine, dopamine and serotonin. WO011820; 2007
   Google Scholar
• AMR Technology, Inc & Bristol-Myers Squibb Co. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines. WO141081; 2008
   Google Scholar
• AMR Technology, Inc & Bristol-Myers Squibb Co. Aryloxy- and heteroaryloxy- substituted tetrahydrobenzazepines and use therefore to block reuptake of norepinephrine, dopamine and serotonin. WO141082; 2008
   Google Scholar
• OTSUKA Pharmaceutical Co., Ltd. In 1-position durch einen ring substitute benzo[1, 4] diazepine zur verwendungs als antidepressiva. JP20111111419; WO145357; 2009
   Google Scholar
• Glaxosmithkine istrazivacki centar Zagreb D.O.O. Tetracyclic monoamine reuptake inhibitors for treatment of CNS diseases and disorders. WO109190; 2006
   Google Scholar
• Tanaka S. 6-amino alkylene 6,7-dihydro-5H-dibenzo[b.g][1,5]thiazocines. US3803143; 1970
   Google Scholar
• Lundbeck A/S. 2-(1H-indolylsulfanyl)-aryl amine derivatives for use in their treatment of affective disorders, pain, ADHD and stress urinary incontinence. WO007843; 2006
   Google Scholar
• Universite De Rouen. Neuroactive plant extract from hypericum polyanthemum. WO092162; 2010
   Google Scholar
• Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. J Psychiatry 2001;158:1843-9
   Google Scholar
• Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-35
   PubMed Web of Science ®Google Scholar
• Suhara T, Takano A, Sudo Y, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003;60:386-91
   PubMed Web of Science ®Google Scholar
• Takano A, Suzuki K, Kosaka J, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 2006;185:395-9
   PubMed Web of Science ®Google Scholar